monomethyl-auristatin-e and Carcinoma--Merkel-Cell

Merkel cell carcinoma (MCC) is an aggressive skin cancer, whose tumour cells often express CD56. While immune checkpoint inhibitors constitute a major advance for treating patients with MCC with advanced disease, new therapeutic options are still urgently required.. To produce and evaluate the therapeutic performance of a new antibody-drug conjugate (Adcitmer. CD56 expression was evaluated in a MCC cohort (immunohistochemistry on a tissue microarray of 90 tumour samples) and MCC cell lines. Interaction of an unconjugated CD56-targeting antibody with CD56. Similar to previous reports, CD56 was expressed by 66% of MCC tumours in our cohort, confirming its relevance as a therapeutic target. Specific binding and internalization of the unconjugated CD56-targeting antibody was validated in MCC cell lines. The high homogeneity of the newly generated Adcitmer. Our study suggests that Adcitmer

Topics: Animals; Carcinoma, Merkel Cell; Humans; Immunohistochemistry; Mice; Oligopeptides; Skin Neoplasms